您的位置:首页  > 论文页面

基因治疗中人体对腺病毒载体的免疫应答

发表时间:2008-08-15  浏览量:1700  下载量:797
全部作者: 徐赫,贺琼,王月丹
作者单位: 北京大学基础医学院
摘 要: 人类腺病毒(adenovirus, Ad)是一种无包膜的DNA病毒,常用的是Ad5与Ad2型。腺病毒载体(adenoviral vectors, AdV)是经去除腺病毒基因组的不同区域而获得的。基因治疗是指以改变细胞遗传物质为基础的治疗,重组腺病毒因其基因组大、转导率高、安全性高的特点被广泛用于基因治疗的载体。机体针对转导后载体的免疫应答是临床治疗上影响治疗效果的主要因素之一,应用腺病毒的体内基因转移已经取得一定成功,但是因为宿主免疫反应引起炎症并限制了转基因表达的数量和持续时间,使得腺病毒介导的基因治疗仍有待改进。本文综述了腺病毒载体的基本特点、机体针对腺病毒载体的天然免疫应答、适应性免疫应答以及重复注射AdV产生的免疫应答。
关 键 词: 免疫学;腺病毒载体;初期免疫应答;适应性免疫应答
Title: The immune response against adenoviral vectors in human gene therapy
Author: XU He, HE Qiong, WANG Yuedan
Organization: School of Basic Medical Sciences, Peking University
Abstract: Adenovirus (Ad) is a kind of DNA virus without envelop, and the most common ones are type Ad5 and Ad2. Adenoviral vector is obtained by deleting some parts of virus genome. Gene therapy is a kind of treatment, which is based on changing the genetic material. Recombinant adenoviral vectors (AdV), which has many advantages, such as big genome, high transduction rate, and high safety, is widely used in gene therapy. The immune response against vectors is a major problem which may affect the result of gene therapy. This article focuses on the characteristics of adenoviral vectors. The innate, adaptive immune responses against adenoviral vectors and also the immune response for repeated injection of AdV are reviewed.
Key words: immunology; adenoviral vectors; primary immune response; adaptive immune response
发表期数: 2008年12月第15期
引用格式: 徐赫,贺琼,王月丹. 基因治疗中人体对腺病毒载体的免疫应答[J]. 中国科技论文在线精品论文,2008,1(15):1656-1661.
 
0 评论数 0
暂无评论
友情链接